Pre-Clinical Cell-Based Therapy for Limbal Stem Cell Deficiency

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Stem Cell Biology

Background:

• The cornea's transparency is vital for vision, maintained by limbal stem cells.
• Damage to limbal stem cells leads to limbal stem cell deficiency (LSCD), causing pain and blindness.
• Current treatments for LSCD involve ex vivo cultured cells, but no consensus exists on the optimal cell type.

Purpose of the Study:

• To review current cell-based therapies for LSCD explored in animal models.
• To identify and discuss potential cell sources for future clinical applications in LSCD treatment.
• To evaluate substrates used for cell culture and transplantation in LSCD therapy.

Main Methods:

• Systematic review of studies on cell-based therapies for LSCD in animal models.
• Analysis of findings focusing on cell culture substrates and transplantation methods.
• Evaluation of various cell types investigated for LSCD treatment efficacy.

Main Results:

• Several cell types beyond limbal epithelial cells (LEC) have been explored in animal models.
• Substrates for cell culture and transplantation significantly impact therapeutic outcomes.
• Epidermal stem cells and hair follicle-derived stem cells show potential as accessible autologous sources.

Conclusions:

• There is no definitive consensus on the best cell type for treating LSCD.
• Epidermal stem cells and hair follicle-derived stem cells are strong candidates for future clinical trials due to accessibility and autologous potential.
• Further research is needed to optimize cell-based therapies and substrates for LSCD treatment.